Published in Chambers Expert Focus. Lauren Murdza and Richard Taylor share their insights on supply chain issues in the life sciences sector in the latest episode of At the Intersection of Science and Law.

Published in Chambers Expert Focus. Lauren Murdza and Richard Taylor share their insights on supply chain issues in the life sciences sector in the latest episode of At the Intersection of Science and Law.

In DLA Piper’s At the Intersection of Science and Law podcast, members of the firm’s Life Sciences team explore the connection between science and the law in areas that include AI and drug discovery, mRNA technology, and the regulatory implications of new drugs and devices.

At the Intersection of Science and Law

Global Life Sciences Supply Chain Insights

In this episode, Quest Diagnostics’ Adam Donat is joined by DLA Piper’s Kirsten Axelsen, Rachel Portman, and Jae Kim to discuss the increasing complexity and cost of clinical trials, new FDA guidance, innovative trial designs and tools, and what’s expected in the new year.

In this episode, Quest Diagnostics’ Adam Donat is joined by DLA Piper’s Kirsten Axelsen, Rachel Portman, and Jae Kim to discuss the increasing complexity and cost of clinical trials, new FDA guidance, innovative trial designs and tools, and what’s expected in the new year.

Revolutionizing Clinical Trials: A discussion on diversity and patient-centric approaches

In this episode, a cross-disciplinary team of FDA regulatory lawyers and life sciences litigators discuss the implications of the mifepristone litigation for life sciences companies as it pertains to citizen petitions, FDA approvals, and strategies manufacturers might consider going forward.

In this episode, a cross-disciplinary team of FDA regulatory lawyers and life sciences litigators discuss the implications of the mifepristone litigation for life sciences companies as it pertains to citizen petitions, FDA approvals, and strategies manufacturers might consider going forward.

Life sciences companies and the risks posed by the mifepristone litigation

DLA Piper’s Roberto Valenti and Ray Miller discuss trade secrets protection in the US and Europe and the peculiarities within the life sciences sector. Our speakers provide pragmatic approaches and suggestions on how to manage trade secrets for both pharmaceutical companies and medical device manufacturers.

DLA Piper’s Roberto Valenti and Ray Miller discuss trade secrets protection in the US and Europe and the peculiarities within the life sciences sector. Our speakers provide pragmatic approaches and suggestions on how to manage trade secrets for both pharmaceutical companies and medical device manufacturers.

Global Life Sciences Supply Chain Insights

In 1 playlist(s)

At the Intersection of Science and Law

Social links

Follow podcast

Recent clips